Bristol Myers Squibb: A Trending Biopharmaceutical Stock with Positive Earnings Outlook

Bristol Myers Squibb's stock has returned -3.6% over the past month, compared to the Zacks S&P 500 composite's -3.6% change. The company is expected to post earnings of $1.46 per share for the current quarter, a year-over-year change of -18.9%. The Zacks Consensus Estimate for the current fiscal year is $6.26, indicating a change of +1.8% from the prior year. The stock has a Zacks Rank #3 (Hold).